Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
BMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7258.412 (Published 12 August 2000) Cite this as: BMJ 2000;321:412Data supplement
The participating centres for UKPDS 36 were Radcliffe Infirmary, Oxford; Royal Infirmary, Aberdeen; General Hospital, Birmingham; Hammersmith Hospital, London; City Hospital, Belfast; Royal Victoria Hospital, Belfast; St Helier Hospital, Carshalton; Whittington Hospital, London; Norfolk and Norwich Hospital; Lister Hospital, Stevenage; Ninewells Hospital, Dundee; Northampton Hospital; Torbay Hospital; Peterborough General Hospital; Scarborough Hospital; Derbyshire Royal Infirmary; Manchester Royal Infirmary; Hope Hospital, Salford; Leicester General Hospital; Royal Devon and Exeter Hospital.
Coordinating centre
Chief investigators: R C Turner, R R Holman; additional investigators: D R Matthews, H A W Neil; Statisticians: I M Stratton, C A Cull, H J McElroy, Z Mehta; biochemist: S E Manley; research associate: V Frighi: consultant statistician: R Peto; epidemiologist: A I Adler; administrator: P A Bassett; end point assessors: D R Matthews (Oxford), A D Wright (Birmingham), T L Dornan (Salford); retinal photography grading: E M Kohner, S Aldington, H Lipinski, R Collum, K Harrison, C MacIntyre, S Skinner, A Mortemore, D Nelson, S Cockley, S Levien, L Bodsworth, R Willox, T Biggs, S Dove, E Beattie, M Gradwell, S Staples, R Lam, F Taylor, L Leung (Hammersmith); dietician: E A Eeley (Oxford); biochemistry laboratory staff: M J Payne, R D Carter, S M Brownlee, K E Fisher, K Islam, R Jelfs, P A Williams, F A Williams, P J Sutton, A Ayres, L J Logie, C Lovatt, M A Evans, L A Stowell; consultant biochemist: I Ross (Aberdeen); Applications Programmer: I A Kennedy; Database clerk: D Croft; ECG Coding: A H Keen, C Rose (Guy's Hospital); Health Economists: M Raikou, A M Gray, A J McGuire, P Fenn (Oxford); Quality of Life Questionnaire: Z Mehta (Oxford), A E Fletcher, C Bulpitt, C Battersby (Hammersmith), J S Yudkin (Whittington); Mathematical Modeller: R Stevens (Oxford).
Clinical centres
M R Stearn, S L Palmer, M S Hammersley, S L Franklin, R S Spivey, J C Levy, C R Tidy, N J Bell, J Steemson, B A Barrow, R Coster, K Waring, L Nolan, E Truscott, N Walravens, L Cook, H Lampard, C Merle, P Parker, J McVittie, I Draisey (Oxford); L E Murchison, A H E Brunt, M J Williams, D W Pearson, X M P Petrie, M E J Lean D Walmsley, F Lyall, E Christie, J Church, E Thomson, A Farrow, J M Stowers, M Stowers, K McHardy, N Patterson (Aberdeen); A D Wright, N A Levi, A C I Shearer, R J W Thompson, G Taylor, S Rayton, M Bradbury, A Glover, A Smyth-Osbourne, C Parkes, J Graham, P England, S Gyde, C Eagle, B Chakrabarti, J Smith, J Sherwell (Birmingham); N W Oakley, M A Whitehead, G P Hollier, T Pilkington, J Simpson, M Anderson, S Martin, J Kean, B Rice, A Rolland, J Nisbet (London, St Georges's); E M Kohner, A Dornhorst, M C Doddridge, M Dumskyj, S Walji, P Sharp, M Sleightholm, G Vanterpool, C Rose, G Frost, M Roseblade, S Elliott, S Forrester, M Foster, K Myers, R Chapman (London, Hammersmith); J R Hayes, R W Henry, M S Featherston, G P R Archbold, M Copeland, R Harper, I Richardson, S Martin, M Foster, H A Davison (City Hospital, Belfast); L Alexander, J H B Scarpello, D E Shiers, R J Tucker, J R H Worthington, S Angris, A Bates, J Walton, M Teasdale, J Browne, S Stanley, B A Davis, R C Strange (Stoke-on-Trent); D R Hadden, L Kennedy, A B Atkinson, P M Bell, D R McCance, J Rutherford, A M Culbert, C Hegan, H Tennet, N Webb, I Robinson, J Holmes, M Foster, J Rutherford, S Nesbitt (Royal Victoria Hospital, Belfast); A S Spathis, S Hyer, M E Nanson, L M James, J M Tyrell, C Davis, P Strugnell, M Booth, H Petrie, D Clark, B Rice, S Hulland, J L Barron (Carshalton); J S Yudkin, B C Gould, J Singer, A Badenoch, S Walji, M McGregor, L Isenberg, M Eckert, K Alibhai, E Marriot, C Cox, R Price, M Fernandez, A Ryle, S Clarke, G Wallace, E Mehmed, J A Lankester, E Howard, A Waite, S MacFarlane (London, Whittington); R H Greenwood, J Wilson, M J Denholm, R C Temple, K Whitfield, F Johnson, C Munroe, S Gorick, E Duckworth, M Flatman, S Rainbow (Norwich); L J Borthwick, D J Wheatcroft, R J Seaman, R A Christie, W Wheatcroft, P Musk, J White, S McDougal, M Bond, P Raniga (Stevenage); J L Day, M J Doshi, J G Wilson, J R Howard-Williams, H Humphreys, A Graham, K Hicks, S Hexman, P Bayliss, D Pledger (Ipswich); R W Newton, R T Jung, C Roxburgh, B Kilgallon, L Dick, M Foster, N Waugh, S Kilby, A Ellingford, J Burns (Dundee); C V Fox, M C Holloway, H M Coghill, N Hein, A Fox, W Cowan, M Richard, K Quested, S J Evans (Northampton); R B Paisey, N P R Brown, A J Tucker, R Paisey, F Garrett, J Hogg, P Park, K Williams, P Harvey, R Wilcocks, S Mason, J Frost, C Warren, P Rocket, L Bower (Torbay); J M Roland, D J Brown, J Youens, K Stanton-King, H Mungall, V Ball, W Maddison, D Donnelly, S King, P Griffin, S Smith, S Church, G Dunn, A Wilson, K Palmer (Peterborough); P M Brown, D Humphriss, A J M Davidson, R Rose, L Armistead, S Townsend, P Poon (Scarborough); I D A Peacock, N J C Culverwell, M H Charlton, B P S Connolly, J Peacock, J Barrett, J Wain, W Beeston, G King, P G Hill (Derby); A J M Boulton, A M Robertson, V Katoulis, A Olukoga, H McDonald, S Kumar, F Abouaesha, B Abuaisha, E A Knowles, S Higgins, J Booker, J Sunter, K Breislin, R Parker, P Raval, J Curwell, H Davenport, G Shawcross, A Prest, J Grey, H Cole, C Sereviratne (Manchester); R J Young, T L Dornan, J R Clyne, M Gibson, I O'Connell, L M Wong, S J Wilson, K L Wright, C Wallace, D McDowell (Salford); A C Burden, E M Sellen, R Gregory, M Roshan, N Vaghela, M Burden, C Sherriff, S Mansingh, J Clarke, J Grenfell (Leicester); J E Tooke, K MacLeod, C Seamark, M Rammell, C Pym, J Stockman, C Yeo, J Piper, L Leighton, E Green, M Hoyle, K Jones, A Hudson, A J James, A Shore, A Higham, B Martin (Exeter)
Committees
UKPDS data committee: C A Cull, V Frighi, R R Holman, S E Manley, D R Matthews, H A W Neil, I M Stratton, R C Turner.
Data monitoring and ethics committee: W J H Butterfield, W R S Doll, R Eastman, F R Ferris, R R Holman, N Kurinij, R Peto, K McPherson, R F Mahler, T W Meade, G Shafer, R C Turner, P J Watkins.
Policy advisory group: C V Fox, D R Hadden, R R Holman, D R Matthews, R C Turner, A D Wright, J S Yudkin.
Steering committee for glucose study: D J Betteridge, R D Cohen, D Currie, J Darbyshire, J V Forrester, T Guppy, R R Holman, D G Johnston, A McGuire, M Murphy, A M el-Nahas, B Pentecost, D Spiegelhalter, R C Turner.
Additional funding: Medical Research Council, British Diabetic Association, the UK Department of Health, the US National Eye Institute and the US National Institute of Diabetes, Digestive and Kidney Disease in the National Institutes of Health, United States, the British Heart Foundation, The Wellcome Trust, Charles Wolfson Charitable Trust, the Clothworkers' Foundation, the Health Promotion Research Trust, the Alan and Babette Sainsbury Trust, The Oxford University Medical Research Fund Committee. Novo-Nordisk, Bayer, Bristol-Myers Squibb, Hoechst, Lilly, Lipha and Farmitalia Carlo Erba. British Diabetic Association members. GlaxoWellcome, SmithKline Beecham, Pfizer, Zeneca, Pharmacia and Upjohn, Boehringer Mannheim, Becton Dickinson, Owen Mumford, Securicor, Kodak and Cortecs Diagnostics.
Related articles
- This Week In The BMJ Published: 12 August 2000; BMJ 321 doi:10.1136/bmj.321.7258.0/b
- Editorial Published: 12 August 2000; BMJ 321 doi:10.1136/bmj.321.7258.394
- Correction Published: 13 January 2001; BMJ 322 doi:
- Letter Published: 12 May 2001; BMJ 322 doi:10.1136/bmj.322.7295.1183
- Letter Published: 31 January 2012; BMJ 344 doi:10.1136/bmj.e735
See more
- Cardiovascular disease: Just one in 12 eligible people had health check last year, watchdog findsBMJ November 13, 2024, 387 q2518; DOI: https://doi.org/10.1136/bmj.q2518
- Semaglutide’s CVD indication could cost US Medicare $145bn extra a yearBMJ August 28, 2024, 386 q1878; DOI: https://doi.org/10.1136/bmj.q1878
- Semaglutide: UK regulator approves drug for prevention of cardiovascular eventsBMJ July 25, 2024, 386 q1660; DOI: https://doi.org/10.1136/bmj.q1660
- Why India is failing to track heatstroke fatalities properlyBMJ July 17, 2024, 386 q1437; DOI: https://doi.org/10.1136/bmj.q1437
- Mail on Sunday articles that accused three commentators of being “statin deniers” were misinformed, judge rulesBMJ June 26, 2024, 385 q1424; DOI: https://doi.org/10.1136/bmj.q1424
Cited by...
- Ocular microvascular complications in diabetic retinopathy: insights from machine learning
- Unraveling shared risk factors for diabetic foot ulcer: a comprehensive Mendelian randomization analysis
- Mediterranean diet and time-restricted eating as a cardiac rehabilitation approach for patients with coronary heart disease and pre-diabetes: the DIABEPIC-1 protocol of a feasibility trial
- Demographic, social and geographic factors associated with glycaemic control among US Veterans with new onset type 2 diabetes: a retrospective cohort study
- Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial
- Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial
- Large and small peripheral arterial disease in persons with type 2 diabetes
- Prevalence of type 2 diabetes by age, sex and geographical area among two million public assistance recipients in Japan: a cross-sectional study using a nationally representative claims database
- Sex differences in the risk of cataract associated with type 2 diabetes: a Mendelian randomization study
- Socioeconomic status and ethnic variation associated with type 2 diabetes mellitus in patients with uncontrolled hypertension in Singapore
- 6. Glycemic Targets: Standards of Medical Care in Diabetes--2021
- Predictors for diabetic retinopathy progression--findings from nominal group technique and Evidence review
- Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week
- Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study
- 6. Glycemic Targets: Standards of Medical Care in Diabetes--2020
- Retinopathy progression and the risk of end-stage kidney disease: results from a longitudinal Japanese cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease
- Incidence and Determinants of Intraocular Lens Implantation in Type 2 Diabetes: The Fremantle Diabetes Study Phase II
- 6. Glycemic Targets: Standards of Medical Care in Diabetes--2019
- A Comparison of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline and the 2017 American Diabetes Association Diabetes and Hypertension Position Statement for U.S. Adults With Diabetes
- Effects of High Blood Pressure on Cardiovascular Disease Events Among Chinese Adults With Different Glucose Metabolism
- Hypertension Management in Diabetes: 2018 Update
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- Current practice of usual clinic blood pressure measurement in people with and without diabetes: a survey and prospective 'mystery shopper study in UK primary care
- Recruitment for exercise or physical activity interventions: a protocol for systematic review
- 6. Glycemic Targets: Standards of Medical Care in Diabetes--2018
- Do We Need a Patient-Centered Target for Systolic Blood Pressure in Hypertensive Patients With Type 2 Diabetes Mellitus?
- Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP
- Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
- Prevalence of metabolic syndrome, discrete or comorbid diabetes and hypertension in sub-Saharan Africa among people living with HIV versus HIV-negative populations: a systematic review and meta-analysis protocol
- Longitudinal Study of Hypertensive Subjects With Type 2 Diabetes Mellitus: Overall and Cardiovascular Risk
- Discovering successful strategies for diabetic self-management: a qualitative comparative study
- 6. Glycemic Targets
- What Should Be the Target Blood Pressure in Elderly Patients With Diabetes?
- PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment
- Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations
- Modest Salt Reduction Lowers Blood Pressure and Albumin Excretion in Impaired Glucose Tolerance and Type 2 Diabetes Mellitus: A Randomized Double-Blind Trial
- Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study
- 5. Glycemic Targets
- Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: cohort study
- Blood pressure lowering in patients with type 2 diabetes improves cardiovascular events including mortality, but more intensive lowering to systolic blood pressure less than 130 mm Hg is associated with further reduction in stroke and albuminuria without further reduction in cardiac events
- Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes
- Association between body mass index and onset of hypertension in men and women with and without diabetes: a cross-sectional study using national health data from the State of Kuwait in the Arabian Peninsula
- Body Mass Index and Heart Failure Among Patients With Type 2 Diabetes Mellitus
- Metformin Treatment in the Period After Stroke Prevents Nitrative Stress and Restores Angiogenic Signaling in the Brain in Diabetes
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- 6. Glycemic Targets
- Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service
- BMI and Coronary Heart Disease Risk Among Low-Income and Underinsured Diabetic Patients
- HDL Cholesterol and Cancer Risk Among Patients With Type 2 Diabetes
- Association between blood pressure and risk of cardiovascular hospital admissions among people with type 2 diabetes
- Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management: Reflections From a Diabetes Care Editors' Expert Forum
- Standards of Medical Care in Diabetes--2014
- Impact of a First-Year Student Pharmacist Diabetes Self-Care Education Program
- Aggressive Blood Pressure Control Increases Coronary Heart Disease Risk Among Diabetic Patients
- Effects of Visit-to-Visit Variability in Systolic Blood Pressure on Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes Mellitus: The ADVANCE Trial
- Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes
- Prognostic Value of Blood Pressure Variability and Average Blood Pressure Levels in Patients With Hypertension and Diabetes
- The Midregional Fragment of Pro-A-Type Natriuretic Peptide, Blood Pressure, and Mortality in a Prospective Cohort Study of Patients With Type 2 Diabetes (ZODIAC-25)
- Incertitude entourant les seuils de pression arterielle systolique chez les personnes diabetiques
- Uncertainty about the systolic blood pressure target in people with diabetes
- Standards of Medical Care in Diabetes--2013
- New Diabetes Diagnostic Threshold of Hemoglobin A1c and the 3-Year Incidence of Retinopathy
- Hypertension revisited
- Type 2 diabetes is a poor example of the overuse of surrogate markers
- Standards of Medical Care in Diabetes--2012
- Community Outreach and Cardiovascular Health (COACH) Trial: A Randomized, Controlled Trial of Nurse Practitioner/Community Health Worker Cardiovascular Disease Risk Reduction in Urban Community Health Centers
- Blood Pressure Control in Diabetes Mellitus: Is Lower Always Better, and How Low Should it Go?
- Benefits of Tight Blood Pressure Control in Diabetic Patients With Hypertension: Importance of early and sustained implementation of effective treatment strategies
- Diabetes, Hypertension, and Outcome Studies: Overview 2010
- Adherence Index Based on the AHA 2006 Diet and Lifestyle Recommendations Is Associated with Select Cardiovascular Disease Risk Factors in Older Puerto Ricans
- Standards of Medical Care in Diabetes--2011
- Controversies in the cardiovascular management of type 2 diabetes
- Cardiovascular Disease and Glycemic Treatment
- The Role of Blood Pressure Variability in the Development of Nephropathy in Type 1 Diabetes
- Managing diabetic retinopathy
- Intensive lowering of systolic blood pressure to a target of less than 120 mm Hg has no effect on the rate of fatal and non-fatal major cardiovascular events in high-risk patients with type 2 diabetes
- Very Intensive Blood Pressure Control Does Not Clearly Reduce Combined Incidence of Cardiovascular Events
- Encounter Frequency and Blood Pressure in Hypertensive Patients With Diabetes Mellitus
- Blood Pressure Management in Patients With Diabetes
- Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients
- Standards of Medical Care in Diabetes--2010
- How to Define Prehypertension in Diabetes/Metabolic Syndrome
- Shifting the Disease Management Paradigm From Glucose: What are the pros?
- Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?
- Hypertension and Diabetes: Should We Treat Early Surrogates?: What are the cons?
- Management of type 2 diabetes: NICE guidelines
- Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study
- Inter-arm blood pressure difference in type 2 diabetes: a barrier to effective management?
- A taxi driver with type 2 diabetes
- Cardiovascular Therapies and Associated Glucose Homeostasis: Implications Across the Dysglycemia Continuum
- Vessel Shrinkage as a Sign of Atherosclerosis Progression in Type 2 Diabetes: A Serial Intravascular Ultrasound Analysis
- Standards of Medical Care in Diabetes--2009